B9D2

Across TCGA pan-cancer cohorts, B9D2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated B9D2 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher B9D2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B9D2 expression acts as an unfavorable survival marker.

LIHC, UCEC, and COAD are the cancer types where B9D2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.093	0.783	<.001	30	view →
UCEC	OS	Median	II,III,IV	0.156	0.768	<.001	24	view →
COAD	OS	Median	All	0.159	0.799	.002	18	view →
BRCA	OS	Median	All	0.131	0.578	.007	16	view →
LUSC	OS	Median	All	0.176	0.724	.018	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
SKCM	DFS	Median	All	0.130	0.737	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

B9D2–LIHC (OS)

Open the LIHC breakdown →